美股新聞 標題聯播 · 近 24 小時 348 則 · 31 個來源 · 最新 9/20 04:16
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · NKTR近 30 天 2 則 · 第 1 / 1 頁
- Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test
- Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
- Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch
- Retail Sales Weaken in July
- U.S. Stock Futures Mixed, Heads for a Winning Week
- Nektar Therapeutics (NKTR) (Q2 2026) Earnings Call Highlights: Respeg Phase 3 Momentum and ...
- Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates
- Nektar Therapeutics Announces Second Quarter 2026 Financial Results
- Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates
- Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
- Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect?
- NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis
- Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。